ArticleMolecular biotechnology2024

Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer.

Jia Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.